STM JOURNALS

Research & Reviews: A Journal of
Pharmaceutical Science

ISSN: 2229-7006
Volume 16, Issue 2, 2025
May–August
DOI (Journal): 10.37591/RRJoPS

https://journals.stmjournals.com/rrjops

Review RRJoPS

Pharmacovigilance: Enhancing Drug Safety Through Technology

Kalyani Ghanshyam Patil[1,*], Akash S. Jain[2], Divakar R. Patil[2], Azam Z. Shaikh[2], Sameer R. Shaikh[2], Hitendra S. Chaudhari[2]

Abstract

The research and practices surrounding the identification, evaluation, and avoidance of hazardous medication responses in people are known as pharmacovigilance. Pharmacovigilance has been defined as a kind of ongoing observation of side effects and other safety-related features of medications that have previously been introduced to the market. Pharmacovigilance has been shown to be crucial in promoting the safe use of medications by disseminating knowledge about the negative effects that pharmaceuticals have on the public. This article provides a quick overview of the relevance, necessity, operation, function, and significance of pharmacovigilance. To ensure the safety of therapies at every stage of development, pharmacovigilance is crucial. It entails continuously monitoring side effects and other unfavorable outcomes linked to medicinal substances after they hit the market. Pharmacovigilance aims to identify any safety concerns through thorough data collection, analysis, and communication, protecting patients and advancing public health. To guarantee the safety of pharmaceutical goods at every stage of their lifespan, pharmacovigilance is essential. It entails continuously monitoring side effects and other unfavorable outcomes linked to medicinal substances after they hit the market. Pharmacovigilance aims to identify any safety concerns through thorough data collection, analysis, and communication, protecting patients and advancing public health.

Keywords: Pharmacovigilance, drug safety, technology, adverse event, signal detection

INTRODUCTION

Pharmacovigilance, according to one definition, is the science and activities surrounding the detection, assessment, retention, and prevention of the adverse effects of drugs or any other possible drug-related problems [1]. Another name for pharmacovigilance, referred to as PV or PhV, is drug safety. The Greek word "pharmakon," denoting "drug," and the Latin word "vigilare," denoting "to keep watch," are the sources of the term "pharmacovigilance" [2]. With the ultimate objective of minimizing hazards and optimizing the benefits of pharmaceuticals, pharmacovigilance (PV) is a crucial instrument for public health [3]. The Australian obstetrician Dr. William McBride first suspected a causal connection between thalidomide use during pregnancy and serious fatal deformities (phocomelia). In December 1961, McBride published a letter in The Lancet introducing PV. In pregnant women, thalidomide was administered as a sedative and antiemetic [4]. The study of pharmacovigilance, often known as drug safety monitoring, is concerned with identifying, evaluating, understanding, and preventing adverse drug reactions (ADRs) [5]. Adverse drug responses (ADRs) are negative side effects that occur after taking medicine. The phrase "pharmacovigilance" refers to the tasks involved in discovering,

***Author for Correspondence**
Kalyani Ghanshyam Patil
E-mail: patilkalyani1702003@gmail.com

[1]Associate Professor, Department of Pharmaceutical Chemistry, Oriental College of Pharmacy, Navi Mumbai, Maharashtra, India.
[2]Manager, Procter and Gamble Home Product Private Limited, Mumbai, Maharashtra, India.

Received Date: March 01, 2025
Accepted Date: May 10, 2025
Published Date: June,16, 2025

Citation: Kalyani Ghanshyam Patil, Akash S. Jain, Divakar R. Patil, Azam Z. Shaikh, Sameer R. Shaikh, Hitendra S. Chaudhari. Pharmacovigilance: Enhancing Drug Safety Through Technology. Research & Reviews: A Journal of Pharmaceutical Science. 2025; 16(2): 38–44p.

evaluating, knowledge, and eliminating side effects associated with prescription medications. Pharmacovigilance is ongoing after the medicine is placed on the market and begins during clinical studies [6]. By (a) advocating the finding of previously not identified adverse drug reactions (ADRs), interactions, and increases in the frequency of known ADRs, (b) identifying risk factors for the development of ADRs, and (c) estimating quantitative parts of benefit/risk analysis and sharing information to enhance drug prescribing and regulation, pharmacovigilance promotes the safe and appropriate use of therapies. Effective drug control programs, public health initiatives, and clinical practice all require pharmacovigilance [1].

It also addresses the wide range of safety-related tasks that a modern pharmaceutical firm needs to be equipped to do, most of which are probably going to fall under the purview of a department that oversees PV [7]. Pharmacovigilance (PV) in the pharmaceutical industry is a relatively new field. PV has grown significantly over the last 20 years and is now influencing many different areas of research and development [8]. It makes a major contribution to the improvement of public health, drug regulation, clinical treatment, and the reduction of potential side effects from licensed pharmaceuticals in the future [9]. Most government entities are speeding up their pharmacovigilance initiatives, including the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [10]. An important part of evaluating, tracking, and averting adverse drug reactions (ADRs) is pharmacovigilance [11].

HISTORY OF PHARMACOVIGILANCE

In India, pharmacovigilance was introduced in 1986. A formal monitoring system for adverse drug reactions (ADRs) was started with 12 regional centers, each with a 50-million-person population. But there was no significant growth [2]. Starting in the first decade of the twenty-first century, pharmacovigilance has started to decline. It should be mentioned that there have been other scandals and crises, such as the FDA's coxib controversy or the AFSSAPS's benfluorex crisis in France [12].

Concerns over medication safety were uncommon in the early years of drug history. Drug regulators and other concerned healthcare providers recognized the necessity of creating a system to ensure medicine safety after the thalidomide tragedy in the 1960s [13]. The underreporting of adverse pharmaceutical responses, which can be attributed to a lack of time and reporting forms, is the largest issue worldwide. The World Health Organization (WHO) established a mechanism to record any adverse medication reactions, as is widely known [14]. The idea of pharmacovigilance is relatively recent, having only been in existence for 170 years. In the field of professional health care, it is a conscious effort that has significant social and economic ramifications. Its objectives are to enhance patient safety, increase quality of life, and evaluate the advantages and disadvantages of medications. In this note, we summarize the achievements in pharmacovigilance. To fully understand the historical progress, one must understand that the initial reports were merely letters or warnings sent by doctors to the publishers of important and well-known scientific publications. Today's reports are highly structured computerized registers. The historical eras also contribute to our understanding. Why was it that pharmacovigilance allowed us to make such major advancements in both the materia medica and human health? And to be aware of the challenges that lie ahead in the future years [15]. Not every medicine that claims to be beneficial is risk-free. Clinical trials can provide a complete picture of a drug's safety profile [16].

PHARMACOVIGILANCE REPORTING AND FUNCTIONING

In India, a pharmaceutical business must fundamentally perform tasks, like collecting, including expedited reporting of major unanticipated adverse reactions and preparations, to meet the regulatory requirements for pharmacovigilance for its marketed medicines [17]. The most often cited obstacle is ignorance of local reporting laws and regulations, as well as the difficulty of linking suspected drug use to ADR etiology. One well-known myth among pharmacists is that they should only report new or serious adverse drug reactions (ADRs). Nearly half of the participants in a UK study assessing hospital pharmacists' knowledge and attitudes regarding ADR reporting were unsure of the kinds of ADRs that needed to be reported [18].

BENEFITS AND RISKS OF PHARMACOVIGILANCE IN MEDICINE REGULATION

A fundamental tenet of the pharmaceutical industry is the notion that randomized clinical trials can determine the safety and efficacy of a medication. The US Food and Drug Administration (FDA) approval procedures and clinical trial processes do not offer a perfect assurance of safety for all potential customers in all situations [19].

ROLE OF PHARMACOVIGILANCE IN MEDICINE REGULATION

Artificial intelligence's function (AI) will have a big impact on everything from genetics to genomics. AI will look for patterns in vast informative databases and medical records, as well as assist in identifying mutations and links to illness. Businesses today are creating a new type of computational technology that can tell doctors about the effects of genetic variety on a cell's DNA, whether it is for medicinal or non-therapeutic reasons. Think about the predicting skills for pharmacovigilance [20].

Clinical Trials

Phases I through III of clinical investigations are carried out in tightly regulated environments with close monitoring of both therapeutic and side effects. For a variety of reasons, extensive clinical testing frequently falls short in identifying medication safety concerns that surface after marketing [21].

- *Phase-0:* Perhaps a first-in-human exploratory trial that followed the FDA's 2006 standards for experimental medicine issued in the United States was recently labeled as phase zero [22].
- *Phase I:* Unit for the first step of human subject testing in the Phase I Path Area. Ideally, there should be a small cluster of healthy volunteers (20–80) [23].
- *Phase-II:* Clinical trial investigations are conducted on a large cluster of patients and volunteers (20–300) to evaluate the drug's efficacy and to continue clinical trial safety evaluation in a larger cluster of patients and volunteers once the study drug's initial safety has been established [24].

Adverse Drug Reaction

An unintentional and unpleasant reaction to a health product that occurs at the levels typically employed or tested for the diagnosis, prevention, or treatment of a disease or the modification of an organic function is known as an adverse drug reaction (ADR) [25]. Because pharmaceutical preparations typically contain more than components, it might be challenging to identify the causal agent linked to adverse drug reactions (ADRs) that are experienced [26]. Adverse drug reactions (ADRs) can occur from every drug, and taking a drug has a risk [27]. The degree of risk must be considered in addition to the anticipated therapeutic benefit when deciding whether to use a particular medicine in a particular patient [28].

Needs of Pharmacovigilance

The goals of pharmacovigilance studies are furthered by educating patients, healthcare professionals, and regulators on how to use medications safely as well as by creating policies and processes for gathering and reviewing patient and physician reports [29].

METHOD INCORPORATED IN PHARMACOVIGILANCE

Spontaneous Reporting System

Since their development, SRSs have supplanted earlier methods as the primary means of acquiring information on the security of medications following their release onto the market. Finding novel, unusual, and important ADR signals as quickly as feasible is the main goal of SRS. A spontaneous reporting system allows doctors, pharmacists, and patients to report suspected adverse drug reactions (ADRs) to a pharmacovigilance center more frequently [30].

Intensive Monitoring

A non-interventional observational cohort serves as the basis for intensive monitoring. Because intensive monitoring is non-interventional and does not use inclusion or selection criteria when collecting data, it provides real-world clinical data [31].

PHARMACOVIGILANCE PROCESSES

Processes Involved

- Collect and record ADRs.
- Causality assessment and analysis of ADRs.
- Collate and code in the database.
- Compute risk benefits and suggest regulatory actions.
- Communicate for safe use of drugs among stakeholders [32].

PHARMACOVIGILANCE IN EMERGENCY HEALTHCARE

Early in the pandemic, there was a rush to repurpose drugs that had previously been approved for use in other contexts due to a shortage of COVID-19 vaccinations and treatments. Because of this, several drugs – including azithromycin, ivermectin, and hydroxychloroquine – have been prescribed off-label to treat COVID-19 patients, even though the supporting data for these drugs' efficacy was mostly derived from in vitro studies and of low quality [33].

Eco Pharmacovigilance

Eco pharmacovigilance plays a vital role in reducing and regulating pharmaceutical pollution by detecting, assessing, and mitigating the adverse effects linked to the presence of pharmaceuticals in the environment [34]. Despite the generally low amounts of medicines found in the environment (between mg/L and g/L), there are still some possible direct and indirect risks for people that require close monitoring [35].

Pharmacovigilance Program

A defined communication plan for routine communication and crisis communication, as well as a national pharmaceutical covigilance advisory group capable of offering technical support on causality assessment, risk assessment, risk management, and case investigation [36].

Adherents of Pharmacovigilance

Several prominent proponents of pharmacovigilance, such as quality assurance and safety centers, are located under the Department of Essential Drugs and Medicines Policy, which is a member of the WHO Health Technology and Pharmaceuticals cluster. Their goal is to close the enormous gap between the potential that essential drugs have to offer and their ability to save lives, with the goal of improving health [37].

Drug Safety Reporting

Pharmacovigilance and reporting of suspected adverse events have as their main objectives determining the drug's risk profile as soon as feasible and identifying the group most at risk. As part of the examination process for safety reports, the probability (causal association or link) of the relationship between medication exposure and the incidence of adverse events is determined. It is important to start by attempting to "prove or disprove it" after suspecting an adverse drug occurrence (a causal relationship) [38].

PHARMACOVIGILANCE FUTURE PROSPECTS

Looking ahead, a strong pharmacovigilance system that can identify novel ADRs and implement the necessary regulatory measures to safeguard public health is anticipated. Information that can support a patient or a healthcare provider in making decisions has not received much attention [39]. Post-marketing surveillance programs are necessary in every nation to monitor the frequency of adverse drug responses since domestic data collection will support national regulatory decisions. These initiatives have the potential to lower hospitalization, healthcare expenses, morbidity, mortality, and liability associated with ADRs [40]. Because of ADR surveillance, patients ought to receive safe and efficient products [41]. The fact that Indian healthcare professionals are more knowledgeable about pharmacovigilance and ADR monitoring could be one reason for the lower prevalence in that country

[42]. For final safety determinations on medications, comparisons of benefit/risk evaluations between pharmaceuticals with relevant indications may be necessary, which makes the process more challenging [43]. HCPs and the public should be integrated in a well-structured program to create synergies for tracking ADRs in the area, since good risk control has a favorable benefit/cost ratio [44]. Patient reports are more detailed, clear, and insightful than HCP reports, which makes them easier to grasp when it comes to ADRs. 9% of all ADR data come via Direct Patient Reporting (DPR) systems, which are presently in use in more than 60 countries; HCPs provide the remaining percent of the data [45].

CONCLUSIONS

Pharmacovigilance evaluates a drug's safety profile by examining all relevant data. The benefit of the medication should also be considered in pharmacovigilance. To systematically identify and correlate medications with side effects and take corrective action, pharmacovigilance is necessary. The best way to evaluate spontaneous reports is to do so within the strict and well-defined framework of the good pharmacovigilance procedure (GPVP), which serves as a functional foundation for business risk management, public health, and health care delivery. These procedures are intended to quickly and accurately identify new and potentially significant information regarding adverse drug reactions, as well as to notify the drug safety professional of it. Pharmacovigilance technologies in the future will be increasingly capable of interoperability and standardization. It is reasonable to say that pharmacovigilance can address the problems caused by the growing variety and potency of medications (including vaccines); yet, putting contemporary pharmacovigilance solutions into practice and embracing them is not without problems. We talked about PV's emphasis on collecting, tracking, looking into, analyzing, and assessing data to reduce the negative consequences in this review paper.

REFERENCES

1. Cioanca O, Hancianu M. Phytotherapy approaches in stress-related disorders. In: 10th International Pharmaceutical Conference "Science and Practice 2019"; 2019 Nov 15. p. 15. Lithuanian University of Health Sciences.
2. Soni R, Kesari B. A review on pharmacovigilance. Int J Pharm Sci Rev Res. 2014;26(2):237–241.
3. Garashi HY, Steinke DT, Schafheutle EI. A systematic review of pharmacovigilance systems in developing countries using the WHO pharmacovigilance indicators. Ther Innov Regul Sci. 2022;56:717–743.
4. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO; 2002. Available from: https://www.who.int/publications/i/item/10665-42493
5. Hamid AAA, Rahim R, Teo SP. Pharmacovigilance and its importance for primary health care professionals. Korean J Fam Med. 2022;43(5):290–295.
6. Sarker A, Ginn R, Nikfarjam A, O'Connor K, Smith K, Jayaraman S, et al. Utilizing social media data for pharmacovigilance: A review. J Biomed Inform. 2015;54:202–212.
7. Beninger P. Pharmacovigilance: An overview. Clin Ther. 2018;40(12):1991–2004.
8. Stagi L, Bocchi I, Bernardini D, Ciappa M, Dellon S, Castiglione GN, et al. The evolution of the pharmacovigilance department in the pharmaceutical industry: Results of an Italian national survey. Ther Adv Drug Saf. 2024;15:20420986241293296.
9. Jeetu G, Anusha G. Pharmacovigilance: A worldwide master key for drug safety monitoring. J Young Pharm. 2010;2(3):315–320.
10. Bihana K, Lebrun-Vignes B, Funck-Brentano C, Salem JE. Uses of pharmacovigilance databases: An overview. Therapies. 2020.
11. Inácio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: A systematic review. Br J Clin Pharmacol. 2017;83:227–246.
12. Caron J, Rochoy M, Gaboriau L, Gautier S. Histoire de la pharmacovigilance. Therapie. 2016;71(2):123–128.
13. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;278(7216):1358.
14. World Health Organization. WHO Policy Perspectives on Medicines: Looking at the

Pharmacovigilance—Ensuring the Safe Use of Medicines. Geneva: WHO; 2004.
15. Fornasier G, Francescon S, Leone R, Baldo P. An historical overview over pharmacovigilance. Int J Clin Pharm. 2018;40(4):744–747.
16. Benyoucef L, Grabot B, editors. Artificial intelligence techniques for networked manufacturing enterprises management. London: Springer; 2010.
17. Norwood PK, Sampson AR. A statistical methodology for postmarketing surveillance of adverse drug reaction reports. Stat Med. 1988;7:1023–1030.
18. Green CF, Mottram DR, Rowe PH, Pirmohamed M. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol. 2001;51(1):81–86.
19. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmacovigilance. Drug Saf. 2005;28:981–1007.
20. Sharma S, Phadnis P, Gajbhiye S. Pharmacovigilance: Its awareness and impact—study in a tertiary care teaching medical college in Central India. Int J Pharm Res Bio Sci. 2013;2:234–247.
21. Kennedy DL. Spontaneous reporting in the United States. Pharmacoepidemiol. 2000;149–174.
22. World Health Organization. Descriptive analysis of COVID-19-related spontaneous reports from VigiBase: interim results [Online]. Geneva: WHO. 2020. Available from: https://www.who.int/medicines/regulation/medicines-safety/ICSRs-COVID19April-12.pdf?ua=1
23. Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 patients in India [Online]. 2020. Available from: https://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(20)30313-3.pdf
24. EU Clinical Trials Register [Online]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=covid-19
25. Maiti B, Nagori BP, Singh R, Kumar P, Upadhyay N. Recent trends in herbal drugs: A review. Int J Drug Res Technol. 2011;1:17–25.
26. Kulkarni MD, Baig MS, Chandaliya KC, Doifode SM, Razvi SU, Sidhu NS. Knowledge, attitude and practice of pharmacovigilance among prescribers of Government Medical College and Hospital, Aurangabad (Maharashtra). Int J Pharmacol Ther. 2013;3:10–18.
27. Chakraverty R, Banerjee A. Emerging issues in pharmacovigilance of herbal medicines in India. Int J Pharm Sci Rev Res. 2013;20:40–42.
28. Lagier G, Vincens M, Castot A. Imputability in drug monitoring: Principles of the balanced drug reaction assessment method and principal errors to avoid. Therapie. 1983;38(3):303–318.
29. Gross FH. The scientific basis of drug safety regulations. In: Drug Safety. Oxford: Pergamon; 1982. 9–18.
30. Domínguez Carrillo LG, Domínguez Gasca LG. Síndrome del tendón del peroneo largo por lesión del Os peroneum. Acta Méd Grupo Ángeles. 2021;19(1):128–129.
31. Kesharwani V, Farooqui M, Kushwaha N, Singh R, Jaiswal P. An overview on pharmacovigilance: A key for drug safety and monitoring. J Drug Deliv Ther. 2018;8:130–135.
32. Patil LB, Patil SS, Hubale SS, Mane RU. Pharmacovigilance: A review. Int J Sci Res Sci Technol. 2015;1(3):25–29.
33. Velo G, Moretti U. Ecopharmacovigilance for better health. Drug Saf. 2010;33:963–968.
34. Trifirò G, Crisafulli S. A new era of pharmacovigilance: Future challenges and opportunities. Front Drug Saf Regul. 2022;2:866898.
35. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci. 2001;22:298–305.
36. Department of CDSCO, Ministry of Health & Family Welfare, Government of India. Protocol for National Pharmacovigilance Programme. 2004.
37. World Health Organization. WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000–2003. Geneva: WHO; 2000.
38. Blanc S, Leuenberger P, Berger JP, Brooke EM, Schelling JL. Judgments of trained observers on adverse drug reactions. Clin Pharmacol Ther. 1999;25:493–498.
39. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Development Safety Update Report E2F. 2010. Available from:

http://www.ich.org/LOB/media/MEDIA4727.pdf.
40. Maqbool M, et al. Drug safety and pharmacovigilance: An overview. J Drug Deliv Ther. 2019;9:543–548.
41. Rawlins MD. Pharmacovigilance: Paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Physicians Lond. 1995;29:41.
42. Ahmad A, Patel I, Balkrishnan R, Mohanta GP, Manna PK. An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. Perspect Clin Res. 2013;4:204.
43. Kalaiselvan V, Srivastava S, Singh A, Gupta SK. Pharmacovigilance in India: Present scenario and future challenges. Drug Saf. 2019;42:339–346.
44. Ara I, Bukhari B, Ara N, Maqbool M. Present status, standardization and safety issues with herbal drugs. Int J Res Pharm Sci Technol. 2020;1:95–101.
45. Margraff F, Bertram D. Adverse drug reaction reporting by patients: An overview of fifty countries. Drug Saf. 2014;37:409–441.

